The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication.

@article{Renneville2009TheFI,
  title={The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication.},
  author={Aline Renneville and Nicolas Boissel and Nathalie Gachard and Dina Naguib and Christian Bastard and St{\'e}phane de Botton and Olivier Nibourel and C{\'e}cile Pautas and Oum{\'e}daly Reman and Xavier Thomas and Claude Gardin and Christine Terr{\'e} and Sylvie Castaigne and Claude Joseph Preudhomme and Herv{\'e} Dombret},
  journal={Blood},
  year={2009},
  volume={113 21},
  pages={5090-3}
}
Mutations of the CCAAT/enhancer binding protein alpha (CEBPA) gene have been associated with a favorable outcome in patients with acute myeloid leukemia (AML), but mainly in those with a normal karyotype. Here, we analyzed the impact of associated cytogenetic abnormalities or bad-prognosis fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) in 53 patients with CEBPA(+) de novo AML treated in the Acute Leukemia French Association trials. We found that only those with a normal… CONTINUE READING